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1. Introduction 
Primary aldosteronism (PAL) is a clinical disorder characterized by excessive production 
and release of aldosterone from the cortical zona glomerulosa of the adrenal gland. The high 
level of circulating aldosterone increases sodium reabsorption with potassium loss in the 
distal tubule, leading to mild hypernatremia, hypertension (HTN), severe hypokalemia, and 
alkalosis. 1,2 Primary aldosteronism, as originally described by Conn in the 1950s.3,4 (PAL)is 
characterized by an increased secretion of aldosterone that seems to be autonomous of the 
renin–angiotensin system, as the secretion of renin is suppressed. PAL represents the most 
common form of secondary hypertension.5,6 In recent years, the large- scale hypertension 
trials, It is now widely recognized that PAL is much more common than previously thought, 
being present in up to 5–13% of unselected hypertensive patients7 and in resistant HTN (BP 
above goal with three or more antihypertensive medications) with a reported prevalence of 
20% to 23% in this group of patients.5,8 As older age and obesity are 2 of the strongest risk 
factors for uncontrolled hypertension, the incidence of resistant hypertension will likely 
increase as the population becomes more elderly and heavier. The prognosis of resistant 
hypertension is unknown, but cardiovascular risk is undoubtedly increased as patients often 
have a history of long-standing, severe hypertension complicated by multiple other 
cardiovascular risk factors such as obesity, sleep apnea, diabetes, and chronic kidney 
disease.5 In ALLHAT, older age, higher baseline systolic blood pressure, LVH, and obesity 
all predicted treatment resistance as defined by needing 2 or more antihypertensive 
medications.  Overall, the strongest predictor of treatment resistance was having CKD as 
defined by a serum creatinine of ≥1.5 mg/dL. Other predictors of the need for multiple 
medications included having diabetes mellitus and living in the southeastern United States. 
African-American participants had more treatment resistance, as did women, such that 
black women had the lowest control rate (59%) and non-black men the highest (70%).8  
Furthermore, experimental and clinical studies showed that excess aldosterone has 
detrimental effects on the heart, brain and kidneys that are partly hypertension-
independent.9 Patients diagnosed with PAL, compared with patients with essential 
hypertension seems to increase the left ventricular wall thickness.10 In addition, aldosterone 
excess appears to independently increase the risk of cardiac fibrosis.11 Likewise, 
mineralocorticoid receptor blockage has been showed to diminish the effects of aldosterone 
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on PAI-1 levels. In recent years, clinical trials have demonstrated an additive effect of 
combined ACEI and aldosterone receptor antagonism on cardiovascular morbidity and 
mortality.12,13 The mechanism, named aldosterone escape, referring to chronic ACEI that 
leads aldosterone to return to baseline concentrations, might clarify the additional effects of 
aldosterone on PAI-1 levels.14,15 We study, administration of an ACEI (fosinopril) and an 
ACEI plus aldosterone antagonist (spironolactone) both caused a significant decrease in 
PAI-1 levels, which might be attributed to aldosterone escape.16 
Several studies have shown that patients with either aldosterone-producing adenoma (APA) 
or idiopathic hyperaldosteronism (IHA) appear to have increased cardiovascular morbidity 
compared with age-, sex-, and systolic and diastolic BP-matched patients with essential 
hypertension.17,18 Patients with PAL, stroke, MI and significantly increased risk of atrial 
fibrillation.19 Optimal BP control and specific management of aldosterone excess by either 
adrenalectomy or medical treatment with mineralocorticoid receptor (MR) antagonists is 
fundamental for the prevention of cardiovascular events in patients with PA.20  
The adverse effects of aldosterone excess stress the importance of establishing the diagnosis 
of PAL and its underlying cause. The most common subtypes of PAL are APA (35% of 
cases) and IHA (60% of cases).21 Many other subtypes of PAL have also been described, 
including primary or unilateral adrenal hyperplasia (2%), pure aldosterone-secreting 
adrenocortical carcinoma (<1%) and ectopic aldosterone- secreting tumours (e.g. neoplasms 
in the ovary or kidney) (<0.1%).22 
2. Clinical findings 
2.1 Symptoms and signs  
The most common findings in PAL, moderate or severe hypertension and hypokalemia. 
PAL patients are often resistant hypertension, hypertension in these patients usually need to 
take control of multiple drug use. In recent studies, only a minority of patients with PAL (9– 
37%) had hypokalemia.23 Although hypokalemia is considered the hallmark of 
hyperaldosteronism, the majority of patients with PAL have normal serum potassium levels. 
Hypokalemia is believed to be a late manifestation of PAL and many patients with PAL may 
present with HTN well before they develop hypokalemia. 6,23 Most symptoms of PAL are 
attributed to hypokalemia, which include muscle weakness, cramping, transient paralysis, 
palpitations, headache, or polyuria.22 
Half the patients with an APA and 17% of those with idiopathic hyperaldosteronism (IHA) 
had serum potassium concentrations less than 3.5 mmol/liter.24 Thus, the presence of 
hypokalemia has low sensitivity and specificity and a low positive predictive value for the 
diagnosis of PAL.  Separation of IHA and APA, IHA to be treated medically, surgically 
corrected if the APA is very important because of an illness. 
2.2 Laboratory findings 
The recently published Guidelines for diagnosis and treatment of PAL outlined for the 
first time the categoriesof hypertensive patients with relatively high prevalence of PAL 
who should undergo a screening test. 1 The screening test should be performed in all 
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patients with: 1) resistant hypertension; 2) hypertension grade 2 or 3; 3) hypertension and 
spontaneous or diuretic-induced hypokalaemia 4) hypertension with adrenal 
incidentaloma; 5)hypertension and a family history of early-onset hypertension or 
cerebrovascular accident at a young age (<40 year); 6) all hypertensive first-degree 
relatives of patients with PAL. 
There is a general consensus that aldosterone:renin ratio (ARR) is the most reliable available 
means for PAL screening; however there is no agreement on either the ARR cut-off or 
whether the absolute aldosterone level should also be taken into account. Aldosterone⁄ renin 
ratios (ARRs) were calculated from these values using the following Formula (ARR): Plasma 
aldosterone (ng/dL)/Plasma renin (ng/mL-h) . Individuals with an ARR of ≥30 were 
suspected of having primary aldosteronism, while an ARR of <30 was considered normal.1 
However, it is now recognized the prevalence is higher (5-13% of all patients with 
hypertension) when the PAC to PRA ratio (ARR) is used to screen for PAL. Measurements 
of PAC and PRA are recommended for the diagnosis of PAL.  
Several factors affect ARR, the most important being antihypertensive therapy: 
mineralocorticoid receptor antagonists and diuretics lead to false-negative results and thus 
should always be withdrawn for at least 4–6 weeks (6– 8 for spironolactone); 
dihydropyridine calcium channel blockers, angiotensin-converting enzyme inhibitors, 
angiotensin II receptor antagonists can potentially, but infrequently, led to false-negative 
results25; in contrast, beta-blockers and central 2-agonists can cause false positives.26 The 
direct renin inhibitor aliskiren lowers PRA, resulting in false-positive ARR for renin 
measured as PRA and false negatives for renin measured.1 
An increased ARR is not diagnostic by itself, and PAL must be confirmed by 
demonstrating over- production of aldosterone. The Endocrine Society guidelines 
recommend the following four confirmatory tests; an oral sodium test, saline infusion test, 
fludrocortisone test and captopril challenge test.1 Patients should receive 12.8 g sodium 
chloride for 3 days in the oral sodium loading test.  The captopril challenge test shows 
excellent sensitivity despite relatively low specificity and due to its simplicity can be 
performed at the outpatient clinic.   
Oral sodium loading test: This test is performed to evaluate the suppression of 
aldosterone by oral sodium loading. The oral sodium loading test is also not practical in 
hypertensive patients because of their high-salt intake, and the intravenous saline 
infusion test is not common as it is dangerous for elderly patients or those with left 
ventricular hypertrophy or a previous myocardial infarction, all of which are commonly 
complicated by PAL.  The most commonly used test to verify the diagnosis oarl sodium 
loading test. Patients should increase their sodium intake to 200 mmol/d (6 g/d)  for 3 
day, verified by 24-h urine sodium content. Patients should receive adequate slow-release 
potassium chloride supplementation to maintain plasma potassium in the normal range. 
Urinary aldosterone is measured in the 24-h urine collection from the morning of d 3 to 
the morning of day 4. PAL is unlikely if urinary aldosterone is lower than 10 µg/24 h (27.7 
nmol/ d) in the absence of renal disease where PAL may coexist with lower measured 
urinary aldosterone levels. Elevated urinary aldosterone excretion >12 µg/24 h (>33.3 
nmol/d) at the Mayo Clinic, >14 µg/24 h (38.8 nmol/d) at the makes PAL highly likely. 
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Urinary aldosterone levels greater than 12 mcg/24 hours indicate failure to suppress the 
aldosterone production by high salt intake and is diagnostic of PAL with over 90% 
sensitivity and specificity.22 
Saline loading test: Patients stay in the recumbent position for at least 1 h before and during 
the infusion of 2 liters of 0.9% saline iv over 4 h, starting at 08:00–09:30 h. Blood samples for 
renin, aldosterone, cortisol, and plasma potassium are drawn at time zero and after 4 h, with 
blood pressure and heart rate monitored throughout the test. Post infusion plasma 
aldosterone < 5 ng/dl make the diagnosis of PAL unlikely, and levels >10 ng/ dl are a very 
probable sign of PAL. Values between 5 and 10 ng/dl are indeterminate.34 SLT is 
contraindicated in patients with severe HTN, chronic kidney failure, HF, cardiac 
dysrhythmias, or severe hypokalemia.  
Captopril challenge test: Patients receive 25–50 mg captopril orally after sitting or standing 
for at least 1 h. Blood samples are drawn for measurement of PRA, plasma aldosterone, and 
cortisol at time zero and at 1 or 2 h after challenge, with the patient remaining seated during 
this period. Plasma aldosterone is normally suppressed by captopril (>30%). The test is 
considered positive if SA remains greater than 12 ng/dL or ARR is greater than 26.28 This 
test has a higher sensitivity (100% versus 95.4%) and specificity (67% to 91% versus 28.3%) 
over the baseline screening tests, and is easier to perform than the SLT.  
Fludrocortisone suppression test: Fludrocortisone suppression is the standard test used 
to confirm the diagnosis of PAL. Fludrocortisone (Florinef) is given 0.1 mg every 6 hours 
orally together with high oral sodium of 200 mmol (6 g) per day for 4 days. Potassium 
supplement should be given to maintain a close to normal serum potassium level. Upright 
SA and PRA are obtained on day 4 of the test. SA greater than 6 ng/dL is indicative of 
failure to suppress the aldosterone production and is diagnostic of PAL; PRA should be 
suppressed to less than 1 ng/mL/hour. FST requires hospital admission because of 
hypokalemia associated with testing as well as the need for frequent blood samples to 
monitor serum potassium levels. This test is contraindicated in patients with severe HTN 
or heart failure (HF). 1,27 
3. Imaging studies 
3.1 Adrenal computed tomography 
Imaging of adrenal glands by computed tomography (CT) and magnetic resonance imaging 
(MRI) is frequently used to detect an adrenal mass in patients with positive screening and 
confirmation tests. 29 
APA may be visualized as small hypodense nodules (usually<2 cm in diameter) on CT. IHA 
adrenal glands may be normal on CT or show nodular changes. Aldosterone-producing 
adrenal carcinomas are almost always more than 4 cm in diameter, but occasionally smaller, 
and like most adrenocortical carcinomas have a suspicious imaging phenotype on CT. 30 
A high resolution CT scan with 2–3 mm cuts represents the best available technique for 
identifying adrenal nodules that can be an APA, primary unilateral adrenal hyperplasia or 
bilateral adrenal hyperplasia.31 According to the Endocrine Society guidelines, MRI, CT or 
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both should be performed in patients with primary aldosteronism to identify the rare but 
large aldosterone-producing carcinoma.32 However, as MRI is more expensive and has a 
lower spatial resolution than CT, MRI has no advantage over CT in subtype evaluation of 
primary aldosteronism.1  
Half of APAs are <20 mm in diameter and up to 42% are <6 mm in diameter, therefore, most 
patients with primary aldosteronism attributable to an APA who can be cured with surgery 
have a small or very small tumor.33 Other surgically curable subtypes of primary 
aldosteronism, such as primary aldosteronism caused by primary unilateral adrenal 
hyperplasia or multinodular unilateral adrenocortical hyperplasia, have nodular lesions that 
are also most often very small (<10 mm in diameter), which makes them hardly detectable 
with CT or MRI. In addition, a nonfunctioning adrenal mass (incidentaloma) can also be 
present in a patient with primary aldosteronism either with a small APA or with unilateral 
adrenocortical hyperplasia, both of which are undetectable with CT. Moreover, in a patient 
with primary aldosteronism, an adrenal nodule can be an APA, a macronodule of hyper-
plasia attributable to idiopathic hyperaldosteronism,34 or a macronodule attributable to 
primary unilateral adrenal hyperplasia.35  
3.2 Adrenal venous sampling 
There are an increasing number of reports that adenal vein sampling (AVS) is the gold 
standard test to differentiate unilateral from bilateral disease in patients with PAL. The 
Endocrine Society guidelines state that AVS is the “standard test to differentiate unilateral 
from bilateral causes of [primary aldosteronism]. 1 Adrenal venous sampling is a difficult 
procedure as the right adrenal vein is small, with the success rate depending on the 
proficiency of the angiographer. AVS is expensive, technically demanding and carries a tiny, 
but not negligible, risk of adrenal-vein rupture.36 
In a study where AVS was used as the gold standard for diagnosis, CT scans mistakenly 
suggested that one-quarter of patients had an APA; correctly identified a unilateral or 
bilateral excess of aldosterone only in half of all patients; falsely suggested a bilateral 
adrenal hyperplasia in one-fifth of patients with a unilateral source of aldosterone excess; 
and in some patients identified an APA in the wrong adrenal gland.34  
Rapid cortisol assays during AVS to monitor cortisol levels can reduce the failure rate of 
AVS. We have developed a new rapid cortisol assay using immunochromatography, in 
which cortisol concentrations can be measured within 6 min. (briefly explain false positive 
rates etc.,  in this method- should this be used in conjunction with CT?) Using this 
technique, the success rate of AVS has improved to 93% .37 
4. Treatment 
At our institution, we support the recommendation from the Endocrine Society guidelines1 
that a lateralized aldosterone secretion should be demonstrated before undertaking surgery 
in patients who are candidates for general anesthesia and wish to achieve long-term cure. 
The goal of treatment for PAL is focused on the normalization of circulating aldosterone or 
aldosterone receptor blockade to prevent the morbidity and mortality associated with HTN, 
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hypokalemia and end-organ damage.29 Management strategies should take patient 
characteristics and desires into consideration. Surgical treatment may not be appropriate for 
all patients with unilateral hypersecreting adrenal mass but may be reasonable for those 
with bilateral hypersecretion. 
4.1 Medical treatment 
Medical management with a mineralocorticoid receptor (MR) antagonist is recommended 
for patients who do not undergo surgery. Medical treatment is recommended for patients 
with bilateral hypersecreting adrenal lesions or for those with unilateral lesion who are not 
optimal for or who do not want surgical treatment (see Pharmacotherapy for 
hyperaldosteronism). Medications that block aldosterone action are effective for the 
treatment of hypokalemia and HTN and these include nonselective (spironolactone) and 
selective aldosterone receptor antagonists (eplerenone). Amiloride is not an aldosterone 
receptor antagonist and is not effective in controlling HTN in PAL but may be used for its 
potassium sparing property. 
Prior studies on the efficacy of spironolactone in treating resistant HTN have used 25 to 50 
mg daily dosing, whereas true PAL may require larger daily doses up to 100 to 400 mg. The 
onset of action on BP may be slow. Measurements of PRA are not necessary but may be an 
indication that an optimal dose of the medication has been prescribed when it is no longer 
suppressed.  
Spironolactone is a nonselective MR antagonist with significant antiandrogenic and 
progestational activities responsible for its most common side effects (gynecomastia, erectile 
dysfunction and abnormal menstrual cycles) 2. Eplerenone is a selective MR antagonist 
without antiandrogen or progesterone agonist activity: it has 60% of the potency of 
spironolactone in vivo and should be administered twice daily given its short half-life. 
Combined therapy with a small dose of spironolactone and amiloride may alleviate these 
undesirable consequences.29 Eplerenone, a more selective mineralocorticoid receptor 
blocker, also effectively reduces BP in patients with resistant hypertension Eplerenone has a 
beter adverse reaction profile because it has substantially less binding affinity to androgen 
and progesterone receptors than spironolactone. 
4.2 Surgical treatment 
Laparoscopic adrenalectomy is currently the best treatment, and can be performed during a 
short hospital stay at a very low operative risk.38-39 This surgery has cured primary 
aldosteronism in 33–72% of patients and resulted in marked improvements in 40–50% of 
patients.40,41 Approximately one-third of all PAL patients has clear lateralization of 
aldosterone production and will benefit from unilateral adrenalectomy. Laparoscopic 
adrenectomy is the most suitable therapy for APA or unilateral adrenal hyperplasia. After 
adrenalectomy hypertension is cured in around 50% of patients with APA (range 33–70%) 
[3] with the remaining patients showing a significant reductions in blood pressure and 
number of antihypertensive drugs. Chronic suppression of the renin-angiotensin axis may 
cause transient postoperative hypoaldosteronism and a liberal sodium diet should be 
allowed to prevent hyperkalemia after the surgery. An I.V. infusion of 0.9% sodium chloride 
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every 8 to 12 hours may be necessary to avoid postoperative intravascular volume 
depletion. All antihypertensive medications, especially spironolactone and amiloride, 
should be withheld and other BP medications may be cautiously reinstituted as needed 
within a few days. The data on follow-up assessment of the remaining adrenal gland after 
surgery is scanty. Postoperative SA, PRA, and ARR are commonly repeated.17 These authors 
also periodically obtained CT scan in their patients at 1 to 3 yearly intervals because they 
have observed that the remaining adrenal gland could slowly increase in size, become 
nodular or develop adenoma after surgery. 
Of note, adrenalectomy in APA patients has also been reported to improve self-assessed 
quality of life. 42 A recent study suggests that, for reasons which are incompletely 
understood, unilateral adrenalectomy may be beneficial in carefully selected patients with 
bilateral PA. 43 
5. Conclusion 
Until recently, aldosterone excess was thought to play a minor role in the development of 
hypertension. Beginning in the early 1990s, however, reports from investigators worldwide 
have found that primary aldosteronism is common in patients with hypertension, with 
prevalence rates of 10 to 15%. In patients with severe or resistant hypertension, the 
prevalence of primary aldosteronism is even higher, with a prevalence of approximately 
20%. Approximately 30% to 60% of APA patients are improved or have resolution of HTN 
and hypokalemia with normal SA and PRA after unilateral adrenectomy. HTN is normally 
resolved within 1 to 6 months and patients with persistent HTN are more likely to be older, 
require more than two antihypertensive drugs preoperatively, or have a longer duration of 
HTN or underlying renal dysfunction. The postoperative BP in those with persistent HTN is 
usually easier to control with fewer medications. The cardiovascular complications of 
patients who achieve optimal BP control with or without medications eventually decrease to 
the levels of those with essential HTN. Partial reversal of renal dysfunction, regression of 
LVM and improved diastolic left ventricular function have been demonstrated after 
successful treatment of PAL. It has been reported that adrenalectomy for APA is more cost-
effective than long-term medical therapy. 
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